MedTrace Logo

Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118

NCT01348724 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-10-15

No results posted yet for this study

Summary

Study to Assess the Absorption, Metabolism and Excretion of \[14C\] NKTR-118 after a Single-Dose Oral Administration.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C] NKTR-118

Single 25 mg oral dose administered on Day 1

Sponsors & Collaborators

Principal Investigators

  • Marianne Kasti, MD · Quintiles, Inc.

  • Mark Sostek, PhD · AstraZeneca

  • Emeline Ramos · AstraZeneca

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01348724 on ClinicalTrials.gov